BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 1, 2024
See today's BioWorld
Home
» ViroPharma’s Picovir Goes Before FDA Panel; Analysts Divided
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
ViroPharma’s Picovir Goes Before FDA Panel; Analysts Divided
March 19, 2002
By
Kim Coghill
No Comments
WASHINGTON In recent days, ViroPharma Inc. has been the subject of speculation surrounding the outcome of today’s government panel hearing on whether to recommend Picovir as a treatment for the common cold. (BioWorld Today)
BioWorld
